Harry Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Richard L. Cassin Editor at Large

Elizabeth K. Spahn Editor Emeritus 

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor

FCPA Blog Daily News

« What's The Impact of Sun's FCPA Disclosure? | Main | The Bourke Files: Lies, Kickbacks And Other Crimes »

Novo Nordisk Pays $18 Million In Penalties For Iraq Bribery

Denmark-based Novo Nordisk A/S will pay a $9 million criminal penalty and enter into a deferred prosecution agreement with the Justice Department for illegal kickbacks paid to the former Iraqi government under the U.N. oil-for-food program. It will also pay $3,025,066 in civil penalties and $6,005,079 in disgorgement of profits, including pre-judgment interest, to the Securities and Exchange Commission.

The DOJ charged Novo in U.S. District Court for the District of Columbia with one count of conspiracy to commit wire fraud and to violate the books and records provisions of the Foreign Corrupt Practices Act.

Novo manufactures insulin, medicines and other pharmaceutical supplies. Between 2001 and 2003, it paid about $1.4 million to the former Iraqi government by inflating the price of contracts by 10 percent before submitting them to the United Nations for approval. It then concealed from the U.N. the amount of the kickbacks included in its prices. Novo also admitted it inaccurately recorded the kickback payments as commissions in its books and records.

The deferred prosecution agreement has a term of three years. The DOJ didn't charge the company under the FCPA's anti-bribery provisions. It said Novo conducted a "thorough review of the illicit payments" and implemented "enhanced compliance policies and procedures. "

In the civil enforcement action, the SEC charged Novo with violating Section 13(b)(2)(A) of the Exchange Act [15 U.S.C. §78m(b)(2)(A)] for failing to keep books, records, and accounts, which, in reasonable detail, accurately and fairly reflected its transactions and dispositions of its assets. It also charged the company under Section13(b)(2)(A) of the Exchange Act [15 U.S.C. § 78m(b)(2)(B)] for failing to devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) payments were made in accordance with management's general or specific authorization; and (ii) payments were recorded as necessary to maintain accountability for its assets.

The SEC said Novo paid kickbacks in three ways:

Initially, Novo Nordisk wired the kickback to [its] Agent's account at the Arab Bank in Amman, Jordan as an advance on his commission. The Agent would then Wire the funds to an official Kimadia account at the Rafidain Bank in Amman, Jordan. [Kimadia is the Iraq State Company for the Importation and Distribution of Drugs and Medical Appliances.] After Kimadia received the kickback payment, the Iraqis authorized the opening of a letter of credit and then Novo Nordisk shipped the goods to Iraq.

Later, Novo Nordisk informed Kimadia that it could not pay the ten percent kickback before it received payment from the U.N. as it was not easy for [Novo's] Athens office to authorize large advance payments to the Agent.

Thereafter, Kimadia no longer required the kickback be made upfront, and instead insisted on a bank guarantee. [The Agent in Jordan] opened a bank guarantee from the Arab Bank payable to Kimadia's account at the Rafidain Bank in Jordan. Eventually, Kimadia informed Novo Nordisk that it would no longer accept bank guarantees paid to its account at the Rafidain Bank. Instead, Kimadia provided Novo Nordisk with an account number where the kickback was to be paid.

Novo Nordisk's ADRs trade on the New York Stock Exchange under the symbol NVO.

Download the DOJ's May 11, 2009 release here.

Download the May 11, 2009 criminal information against Novo Nordisk A/S here.

View the SEC's Litigation Release No. 21033 dated May 11, 2009 in Securities & Exchange Commission v. Novo Nordisk A/S, Civil Action No. 1:09-CV-00862 (D.D.C.) (EGS) here.

Download the SEC's civil complaint against Novo Nordisk here.

Reader Comments (2)

Although this occurred some time ago this is very unfortunate that Novo became involved in such a scheme.

Frankly, sometimes doing business in some cultures can really force businesses to compromise their own accepted standards of conduct. Hopefully, this can be a lesson to everyone who may be put in such a position.

July 6, 2009 | Unregistered CommenterBill R.

It would be interesting to check what Novo Nordisk and other pharmaceutical companies are doing in the developing world. It seems that both in business ethics and policies they have a double standard.

November 1, 2009 | Unregistered CommenterAnonymous

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
All HTML will be escaped. Hyperlinks will be created for URLs automatically.